IP Library Granted Patent US 6,991,776
Granted Patent B2
US 6,991,776 · App. 10/331,854 · Granted Jan 31, 2006

Intracorporeal medicaments for high energy phototherapeutic treatment of disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,991,776
App. No.
10/331,854
Granted
Jan 31, 2006
Kind
B2
Abstract

New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation. In embodiments of the present invention, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

Claims (6)

1. A method of treating diseased tissue from disorders selected from the group consisting of hyperplasia, dysplasia, neoplasia, benign tumors, malignant tumors, resected tumor beds, benign proliferative disorders, malignant proliferative disorders, vascular plaque, inflammation, and infection of human or animal tissue comprising:

administering an intracorporeal radiosensitizer medicament having an active ingredient consisting of at least one halogenated xanthene into or proximate to said human or animal tissue, wherein said halogenated xanthene contains at least four halogen atoms selected from the group consisting of iodine and bromine; and

applying ionizing radiation to said human or animal tissue, wherein said applied ionizing radiation is selected from the group consisting of x-rays, gamma rays, and ionizing radiation having an energy greater than 1 keV and less than 1000 MeV, and wherein said medicament present within or proximate to said tissue increases the efficiency of conversion of said applied ionizing radiation into localized therapeutic effects.

2. The method of claim 1 wherein said human or animal tissue comprises the skin, the mouth and digestive tract, the urinary and reproductive tracts, the respiratory tract, the circulatory system, the head and neck, the endocrine and lymphoreticular systems, connective tissue, tissue surfaces exposed during surgery, and tissue with microbial, viral, fungal, or parasitic infection.

3. The method of claim 1 wherein said halogenated xanthene is Rose Bengal.

4. The method of claim 1 wherein said halogenated xanthene is 4,5,6,7-Tetrabromoerythrosin.

Assignments (25)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2018
From: DEES, H. CRAIG; SCOTT, TIMOTHY C.; WACHTER, ERIC A.; FISHER, WALTER G.; SMOLIK, JOHN T.
To: PHOTOGEN, INC.
Reel/Frame 045896/0775 →
CHANGE OF NAME Recorded May 24, 2018
From: PROVECTUS PHARMACEUTICALS, INC.
To: PROVECTUS BIOPHARMACEUTICALS, INC.
Reel/Frame 046239/0975 →
SECURITY INTEREST Recorded Apr 10, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: WACHTER, ERIC A.
Reel/Frame 045879/0779 →
SECURITY INTEREST Recorded Apr 10, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: LARCEN, MARDELL
Reel/Frame 045489/0699 →
SECURITY INTEREST Recorded Apr 10, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: MILLENNIUM TRUST CO. LLC
Reel/Frame 045489/0315 →
SECURITY INTEREST Recorded Apr 10, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: TIMOTHY WILLIAMS REVOCABLE TRUST
Reel/Frame 045489/0193 →
SECURITY INTEREST Recorded Apr 10, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: TROUT, JONH W.; TROUT, JOSH HUDSON
Reel/Frame 045877/0656 →
SECURITY INTEREST Recorded Apr 9, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: SCOTT, TIMOTHY C.; SCOTT, LEIGH ANNE
Reel/Frame 045478/0270 →
SECURITY INTEREST Recorded Apr 9, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: FORTUNATO, PAUL M.; FORTUNATO, KATHLEEN E.
Reel/Frame 045478/0511 →
SECURITY INTEREST Recorded Apr 9, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: HANSEN, CHRIS; HANSEN, STEPHANIE
Reel/Frame 045480/0437 →
SECURITY INTEREST Recorded Apr 9, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: MORRIS, JEFFREY A.
Reel/Frame 045480/0690 →
SECURITY INTEREST Recorded Apr 9, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: SMITH, GREGORY LYNN
Reel/Frame 045480/0960 →
SECURITY INTEREST Recorded Apr 9, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: MILLENNIUM TRUST CO. LLC
Reel/Frame 046437/0748 →
SECURITY INTEREST Recorded Aug 9, 2017
From: PROVECTUS PHARMATECH, INC.; PROVECTUS BIOPHARMACEUTICALS, INC.
To: TED R. WATSON REVOCABLE TRUST
Reel/Frame 043244/0210 →
SECURITY INTEREST Recorded Aug 1, 2017
From: PROVECTUS PHARMATECH, INC.; PROVECTUS BIOPHARMACEUTICALS, INC.
To: PATRICIA F. BISCHOFF REVOCABLE TRUST
Reel/Frame 043156/0410 →
SECURITY INTEREST Recorded Jun 26, 2017
From: PROVECTUS PHARMATECH, INC.; PROVECTUS BIOPHARMACEUTICALS, INC.
To: TAUSK, SCOTT A.; TAUSK, SANDRA J.
Reel/Frame 042809/0755 →
SECURITY INTEREST Recorded Apr 21, 2017
From: PROVECTUS PHARMATECH, INC.; PROVECTUS BIOPHARMACEUTICALS, INC.
To: MORRIS, JEFFREY A.
Reel/Frame 042091/0421 →
SECURITY INTEREST Recorded Apr 4, 2017
From: PROVECTUS PHARMATECH, INC.; PROVECTUS BIOPHARMACEUTICALS, INC.
To: WACHTER, ERIC A.; CAL ENTERPRISES LLC
Reel/Frame 042188/0389 →
RELEASE OF SECURITY INTEREST Recorded Apr 27, 2007
From: DCOFI MASTER LDC
To: PROVECTUS PHARMATECH, INC.
Reel/Frame 019215/0778 →
RELEASE OF SECURITY INTEREST Recorded Apr 27, 2007
From: DCOFI MASTER LDC
To: PROVECTUS PHARMACEUTICALS, INC.
Reel/Frame 019215/0669 →
SECURITY AGREEMENT Recorded Jun 13, 2005
From: PROVECTUS PHARMATECH, INC.
To: DCOFI MASTER LDC, AS AGENT
Reel/Frame 016127/0687 →
SECURITY AGREEMENT Recorded Jun 13, 2005
From: PROVECTUS PHARMACEUTICALS, INC.
To: DCOFI MASTER LDC, AS AGENT
Reel/Frame 016127/0746 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2004
From: XANTECH PHARMACEUTICALS, INC.
To: PROVECTUS PHARMATECH, INC.
Reel/Frame 014763/0854 →
CHANGE OF NAME Recorded Feb 25, 2003
From: PHOTOGEN, INC.
To: VALEY PHARMACEUTICALS, INC.
Reel/Frame 013782/0476 →
MERGER Recorded Feb 20, 2003
From: VALLEY PHARMACEUTICALS, INC.
To: XANTECH PHARMACEUTICALS, INC.
Reel/Frame 013782/0211 →